- Home
- VNO vs BLCO Comparison
VNO vs BLCO Comparison
Compare VNO & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | BLCO |
|---|---|---|
| Founded | 1946 | 1853 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Ophthalmic Goods |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | VNO | BLCO |
|---|---|---|
| Price | $29.34 | $17.63 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 13 |
| Target Price | ★ $36.82 | $17.25 |
| AVG Volume (30 Days) | ★ 2.2M | 367.7K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $7.45 |
| Revenue Next Year | $4.35 | $5.49 |
| P/E Ratio | $7.08 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $28.08 | $10.45 |
| 52 Week High | $43.37 | $17.91 |
Technical Indicators
Market Signals| Indicator | VNO | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 62.46 |
| Support Level | $28.54 | $16.25 |
| Resistance Level | $30.14 | $17.91 |
| Average True Range (ATR) | 1.40 | 0.60 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 27.35 | 93.08 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.